热门资讯> 正文

Insulet因风险增加而在Oppenheimer降级

2026-08-06 02:52

Oppenheimer lowered Insulet (PODD) to perform from outperform, citing growing risks from a softer-than-expected growth outlook.
The bank also removed its price target.
The downgrade came as the insulin pump maker's Q2 double beat was overshadowed after lowering its full-year revenue outlook.
Insulet believes type 2 diabetes "challenges are execution issues; we believe these are more structural in nature," analyst Suraj Kalia wrote.
"Not only is patient retention an issue, but utilization will also remain a concern long term," he added.

More on Insulet

Insulet Corporation (PODD) Q2 2026 Earnings Call Transcript
Insulet Corporation 2026 Q2 - Results - Earnings Call Presentation
Insulet Corporation: A High-Quality Growth Story Trading At A Reasonable PEG
Insulet forecasts 2026 revenue growth of 20%-22% as it adjusts U.S. assumptions on type 2 retention
Insulet sends Tandem, DexCom lower after guidance cut

推荐文章

风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。